MedTech & Diagnostics
Axogen Executive Compensation (FY25)
AXGN · Executive and director compensation, fiscal 2022 to 2025
Chief executive, fiscal 2025 ◇ Michael Dale | Median of the other named officers $2,261,741 5 officers, excluding the chief executive | Latest say-on-pay support = June 23, 2026 | Chief executive pay ratio ◇ To the median employee |
Velarion Member: every covered company in MedTech & Diagnostics, with dashboards, peer screens and board-ready briefs. Three seats, one year.
The Axogen brief, $1,500
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
Both reports for $2,400.
Data as of October 22, 2026Latest filing (8-K): June 23, 2026
14 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Velarion Member, one year
317 figures on this page: 308 cited to the filing that reported them, 9 calculated from figures it prints. See the citations
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Michael Dale: $8,847,922 → $9,047,454 (2.3% higher)
CEO pay ratio: 104:1 → 80:1 (23.1% lower)
Frequently asked questions
Answers drawn from the data on this page.
Who is Axogen's chief executive and what were they paid?
Michael Dale, Chief Executive Officer and President, received $9,047,454 in total compensation for fiscal 2025. Dale's total moved 2.3% higher from the $8,847,922 reported for fiscal 2024.
What was Axogen's say-on-pay result?
For fiscal 2025, shareholders backed the say-on-pay proposal with 96.5% of votes cast for or against in favor at the meeting held June 23, 2026.
Which companies are in Axogen's peer group?
Companies named in the disclosed peer group include Alphatec Holdings, Inc., AngioDynamics, Inc., Artivion, Inc., AtriCure, Inc. and Bioventus Inc., among others.
What is Axogen's chief executive pay ratio?
The disclosed chief executive pay ratio for fiscal 2025 is 80:1, against median employee compensation of $112,618.
Executive compensation
Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Karen Zaderej President, CEO | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Peter Mariani Executive Vice President , CFO | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Eric Sandberg Former Chief Commercial Officer Departed during or after this year | ◇ | — | ◇ | ◇ | — | — | ◇ | ◇ |
Angelo Scopelianos Chief Research and Development Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | — not reconciled |
Bradley Ottinger General Counsel and Chief Compliance Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Michael Donovan Vice President of Operations | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Fiscal 2023
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Karen Zaderej CEO and President | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Peter Mariani Executive Vice President, CFO | ◇ | — | ◇ | ◇ | — | — | ◇ | ◇ |
Angelo Scopelianos Chief Research and Development Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Michael Donovan Vice President, Operations | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Erick DeVinney Vice President, Peripheral Nerve Science | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Nir Naor CFO | ◇ | — | — | — | ◇ | — | — | ◇ |
Fiscal 2024
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Michael Dale CEO and President | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
Nir Naor CFO | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
Karen Zaderej Former CEO and President Departed during or after this year | ◇ | — | — | — | ◇ | — | ◇ | ◇ |
Erick DeVinney Chief Innovation Officer | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
Marc Began EVP, GC | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
Jens Kemp Chief Marketing Officer | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
Fiscal 2025
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Michael Dale Chief Executive Officer and President | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
Marc Began Executive Vice President, General Counsel and Chief Compliance Officer | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
Jens Kemp Chief Marketing Officer | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
Erick DeVinney Chief Innovation Officer | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
Lindsey Hartley Chief Financial Officer | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
Nir Naor Former Chief Financial Officer Departed during or after this year | ◇ | — | — | — | — | — | ◇ | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.
Equity awards granted
Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
| Officer | Award | Grant date | Threshold units | Target units | Units granted | Maximum units | Exercise price | Grant date fair value |
|---|---|---|---|---|---|---|---|---|
| Erick DeVinney | PSU | ◇ | ◇ | ◇ | — | ◇ | — | ◇ |
| Erick DeVinney | PSU | ◇ | — | ◇ | — | — | — | ◇ |
| Jens Kemp | PSU | ◇ | — | ◇ | — | — | — | ◇ |
| Jens Kemp | PSU | ◇ | ◇ | ◇ | — | ◇ | — | ◇ |
| Lindsey Hartley | PSU | ◇ | ◇ | ◇ | — | ◇ | — | ◇ |
| Lindsey Hartley | PSU | ◇ | — | ◇ | — | — | — | ◇ |
| Lindsey Hartley | PSU | ◇ | — | ◇ | — | — | — | ◇ |
| Lindsey Hartley | PSU | ◇ | ◇ | ◇ | — | ◇ | — | ◇ |
| Marc Began | PSU | ◇ | ◇ | ◇ | — | ◇ | — | ◇ |
| Marc Began | PSU | ◇ | — | ◇ | — | — | — | ◇ |
| Michael Dale | PSU | ◇ | — | ◇ | — | — | — | ◇ |
| Michael Dale | PSU | ◇ | ◇ | ◇ | — | ◇ | — | ◇ |
Fiscal 2022, 2023 are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.
Outstanding awards
Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
| Officer | Award | Unvested units | Market value of unvested units | Exercise price | Expires |
|---|---|---|---|---|---|
| Lindsey Hartley | Option | ◇ | — | ◇ | 3/16/2033 |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 3/16/2032 | |
| Jens Kemp | Option | ◇ | — | ◇ | 3/1/2033 |
| PSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Erick DeVinney | Option | ◇ | — | ◇ | 3/16/2033 |
| RSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 3/16/2032 | |
| Marc Began | Option | ◇ | — | ◇ | 3/1/2033 |
| PSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Michael Dale | PSU | ◇ | ◇ | — | — |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Severance and change in control
The terms as written in the agreements.
Erick DeVinney
Chief Innovation Officer · Terms as described in the company’s compensation discussion · citing a 2026 filing
| Severance cash amount | ◇ |
Jens Kemp
Chief Marketing Officer · Terms as described in the company’s compensation discussion · citing a 2026 filing
| Severance cash amount | ◇ |
Lindsey Hartley
Chief Financial Officer · Amended agreement
| Non-compete period | ◇ |
| Non-solicit period | ◇ |
| Clawback | ◇ |
Marc Began
Executive Vice President, General Counsel and Chief Compliance Officer · Terms as described in the company’s compensation discussion · citing a 2026 filing
| Severance cash amount | ◇ |
Michael Dale
Chief Executive Officer and President · Terms as described in the company’s compensation discussion · citing a 2026 filing
| Severance cash amount | ◇ |
Director compensation
What each non-employee director was paid.
Fiscal 2025
| Director | Fees earned in cash | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|
Paul Thomas Board chair | ◇ | ◇ | — | — | — | — | ◇ |
William Burke | ◇ | ◇ | — | — | — | — | ◇ |
Amy Wendell | ◇ | ◇ | — | — | — | — | ◇ |
Alan M. Levine | ◇ | ◇ | — | — | — | — | ◇ |
John H. Johnson | ◇ | ◇ | — | — | — | — | ◇ |
Kathy Weiler | ◇ | ◇ | — | — | — | — | ◇ |
Joseph Tyndall | ◇ | ◇ | — | — | — | — | ◇ |
Guido Neels | ◇ | — | — | — | — | — | ◇ |
Michael Dale served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
Earlier years are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director fee schedule
The standing retainers and premiums the board pays, as published.
| Board cash retainer | ◇ |
| Board equity retainer | ◇ |
| Board chair premium | ◇ |
| Audit committee chair | ◇ |
| Audit committee member | ◇ |
| Compensation committee chair | ◇ |
| Compensation committee member | ◇ |
Disclosed peer group
The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
- Alphatec Holdings, Inc. ATEC
- AngioDynamics, Inc. ANGO
- Artivion, Inc. AORT
- AtriCure, Inc. ATRC
- Bioventus Inc. BVS
- OrthoPediatrics, Corp. KIDS
- Paragon 28, Inc. FNA
- SI-BONE, Inc. SIBN
- Silk Road Medical, Inc. SILK
- STAAR Surgical Company STAA
- Tactile Systems Technology, Inc. TCMD
- Treace Medical Concepts, Inc. TMCI
- Zynex, Inc. ZYXI
Say-on-pay history
Shareholder support for the compensation program, by year.
| Year | Meeting | Support | Votes for | Votes against | Abstentions |
|---|---|---|---|---|---|
| 2025 | June 23, 2026 | = | ◇ | ◇ | ◇ |
| 2024 | June 18, 2025 | = | ◇ | ◇ | ◇ |
| 2023 | June 5, 2024 | = | ◇ | ◇ | ◇ |
| 2022 | August 15, 2023 | = | ◇ | ◇ | ◇ |
| 2021 | May 25, 2022 | = | ◇ | ◇ | ◇ |
| 2020 | May 10, 2021 | = | ◇ | ◇ | ◇ |
| 2019 | May 28, 2020 | = | ◇ | ◇ | ◇ |
| 2018 | August 14, 2019 | = | ◇ | ◇ | ◇ |
| 2015 | May 26, 2016 | = | ◇ | ◇ | ◇ |
Chief executive pay ratio
As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇
Chief executive total compensation
◇
Velarion Pro: every company page, peer tools and exports, one seat
One seat, one person. It opens the whole platform: the peer tools, the written analysis and the exports, on every company we cover. Join the list and you will hear from us when it opens.
Ask our research desk — $99, 24h, every figure cited to its filing.
Sample answer — “What is the CEO’s total compensation?”
- Michael Dale (Chief Executive Officer and President), FY2025 total compensation $9,047,454 (base salary $775,865) [exec_comp, SEC accession 0000805928-26-000057, filed 2026-04-29]What this page does not include
Everything above is a fact Axogen disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Axogen sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $499Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion IntelligenceAdviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about accessMultiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion IntelligenceCitations
Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
317 figures on this page: 308 cited to the filing that reported them, 9 calculated from figures it prints.
308 cited to the filing
9 calculated from the filing
Documents cited
- 0000805928-26-000081Item 5.07. Submission of Matters to a Vote of Security Holders
- 0000805928-26-000057CEO Pay Ratio · Compensation Discussion and Analysis · DIRECTOR COMPENSATION · Grants of Plan-Based Awards Table · and 2 more sections
- 0000805928-25-000146Exhibit
- 0000805928-25-000095Item 5.07. Submission of Matters to a Vote of Security Holders
- 0000805928-25-000059Summary Compensation Table
- 0000805928-24-000079
- 0000805928-24-000066Summary Compensation Table
- 0000805928-23-000102
- 0000805928-23-000079Summary Compensation Table
- 0000805928-22-000061
- 0000805928-21-000088
- 0001558370-20-007188
- 0001558370-19-008242
- 0001558370-16-006237
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Axogen executive compensation, FY2022–FY2025.” https://intel.velarion.ai/comp/AXGN (accessed 2026).
Short form: data: Velarion
The Axogen brief, $1,500
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
Both reports for $2,400.
14 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Axogen and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
MedTech & Diagnostics rankings
Peers Axogen discloses
The companies named in AXGN's own disclosed peer group.
Terms on this page
Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.
Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
author = {{Velarion Company Intelligence}},
title = {Velarion database: executive and board compensation data},
year = {2026},
version = {2026Q3},
doi = {10.5281/zenodo.22283854},
publisher = {Zenodo},
url = {https://doi.org/10.5281/zenodo.22283854}
}